Product holds potential for replacing glucocorticoids in Duchenne muscular dystrophy and other chronic inflammatory states SILVER SPRING, M.D./ CHICAGO – February 18, 2015 – ReveraGen BioPharma today announced the start of a Phase 1, first-in-human, clinical trial of a novel dissociative steroidal drug, VBP15, under development for Duchenne muscular dystrophy. Recruitment in the trial is . . .
Dear ALS Community, We are excited and enthusiastic about the new approaches and new drugs that are being tested for people with ALS and remain very hopeful that one or more of these will become a therapy with substantial impact on slowing down or perhaps even stopping ALS. We remain grateful to the brave volunteers . . .